Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial.
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA3500-LBA3500
Keyword(s):
LBA3500^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA5503-LBA5503
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. CRA1002-CRA1002
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA4024-LBA4024
Keyword(s):
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. CRA3503-CRA3503
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA5002-LBA5002
◽
Keyword(s):
2017 ◽
Vol 35
(15_suppl)
◽
pp. LBA9007-LBA9007
◽
Keyword(s):
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS3621-TPS3621
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA4500-LBA4500
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA10502-LBA10502
Keyword(s):